• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Athira Pharma Inc. (Amendment)

    1/30/23 1:38:15 PM ET
    $ATHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ATHA alert in real time by email
    SC 13G/A 1 athi22a1.htm athi22a1.htm - Generated by SEC Publisher for SEC Filing  

          CUSIP NO. 04746L104                           13G                            Page 1 of 12

     

     

                                                                                 UNITED STATES

                                                            SECURITIES AND EXCHANGE COMMISSION

                                                                        Washington, D.C. 20549

     

                                                                                  SCHEDULE 13G

     

                                                     Under the Securities Exchange Act of 1934

                                                                             (Amendment No.1)*

     

                                                                           Athira Pharma, Inc.

                                                                              (Name of Issuer)

     

                                                     Common Stock, $0.0001 par value per share

                                                                (Title of Class of Securities)

     

                                                                                     04746L104

                                                                                (CUSIP Number)

     

                                                                             December 31, 2022

     

                                       (Date of Event Which Requires Filing of this Statement)

     

        Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

        [X] Rule 13d‑1(b)

        [ ] Rule 13d‑1(c)

        [ ] Rule 13d‑1(d)

     

        *The remainder of this cover page shall be filled out for a reporting person's initial

        filing on this form with respect to the subject class of securities, and for any subsequent

        amendment containing information which would alter the disclosures provided in a prior cover

        page.

     

        The information required in the remainder of this cover page shall not be deemed to be

        "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or

        otherwise subject to the liabilities of that section of the Act but shall be subject to all

        other provisions of the Act (however, see the Notes).

     

     


     
     

          CUSIP NO. 04746L104                           13G                            Page 2 of 12

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Franklin Resources, Inc.

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          Delaware

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

              5.    SOLE VOTING POWER

     

                          (See Item 4)

     

              6.    SHARED VOTING POWER

     

                          (See Item 4)

     

              7.    SOLE DISPOSITIVE POWER

     

                          (See Item 4)

     

              8.    SHARED DISPOSITIVE POWER

     

                          (See Item 4)

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                          0

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          0.0%

     

              12.   TYPE OF REPORTING PERSON

     

                          HC, CO (See Item 4)

     


     
     

          CUSIP NO. 04746L104                           13G                            Page 3 of 12

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Charles B. Johnson

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          USA

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

              5.    SOLE VOTING POWER

     

                          (See Item 4)

     

              6.    SHARED VOTING POWER

     

                          (See Item 4)

     

              7.    SOLE DISPOSITIVE POWER

     

                          (See Item 4)

     

              8.    SHARED DISPOSITIVE POWER

     

                          (See Item 4)

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                          0

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          0.0%

     

              12.   TYPE OF REPORTING PERSON

     

                          HC, IN (See Item 4)

     


     
     

          CUSIP NO. 04746L104                           13G                            Page 4 of 12

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Rupert H. Johnson, Jr.

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          USA

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

              5.    SOLE VOTING POWER

     

                          (See Item 4)

     

              6.    SHARED VOTING POWER

     

                          (See Item 4)

     

              7.    SOLE DISPOSITIVE POWER

     

                          (See Item 4)

     

              8.    SHARED DISPOSITIVE POWER

     

                          (See Item 4)

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                          0

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          0.0%

     

              12.   TYPE OF REPORTING PERSON

     

                          HC, IN (See Item 4)

     


     
     

         

          CUSIP NO. 04746L104                           13G                            Page 5 of 12

     

     

              Item 1.

     

              (a)   Name of Issuer

     

                          Athira Pharma, Inc.

     

              (b)   Address of Issuer's Principal Executive Offices

     

               18706 North Creek Parkway, Suite 104

               Bothell, WA 98011

     

              Item 2.

     

              (a)   Name of Person Filing

                          (i):   Franklin Resources, Inc.

     

                          (ii):  Charles B. Johnson

     

                          (iii): Rupert H. Johnson, Jr.

     

                         

              (b)   Address of Principal Business Office or, if none, Residence

     

                          (i), (ii), and (iii):

                                      One Franklin Parkway

                                      San Mateo, CA 94403‑1906

                        

              (c)   Citizenship

     

                          (i):     Delaware

     

                          (ii) and (iii): USA

     

                         

     

              (d)   Title of Class of Securities

     

                          Common Stock, $0.0001 par value per share

     

              (e)   CUSIP Number

     

                          04746L104

     

     


     
     

          CUSIP NO. 04746L104                           13G                            Page 6 of 12

     

     

            Item 3. If this statement is filed pursuant to §§240.13d‑1(b) or 240.13d‑2(b) or (c),

                            check whether the person filing is a:

                          (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

                          (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

                          (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C.

                                          78c).

     

                          (d) [ ] Investment company registered under section 8 of the Investment Company

                                          Act of 1940 (15 U.S.C 80a‑8).

     

                          (e) [ ] An investment adviser in accordance with §240.13d‑1(b)(1)(ii)(E);

     

                          (f) [ ] An employee benefit plan or endowment fund in accordance with

                                          §240.13d‑1(b)(1)(ii)(F);

     

                          (g) [X] A parent holding company or control person in accordance with

                                          §240.13d‑1(b)(1)(ii)(G);

     

                          (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit

                                          Insurance Act (12 U.S.C. 1813);

     

                          (i) [ ] A church plan that is excluded from the definition of an investment

                                          company under section 3(c)(14) of the Investment Company Act of 1940 (15

                                          U.S.C. 80a‑3);

     

                          (j) [ ] A non‑U.S. institution in accordance with §240.13d‑1(b)(ii)(J);

     

                          (k) [ ] Group, in accordance with §240.13d 1(b)(1)(ii)(K).

     

                          If filing as a non‑U.S. institution in accordance with §240.13d‑1(b)(1)(ii) (J).

                          please specify the type of institution:

     

              Item 4. Ownership

     

                The securities reported herein are beneficially owned by one or more open or closed end

                investment companies or other managed accounts that are investment management clients of

                investment managers that are direct and indirect subsidiaries (each, an “Investment

                Management Subsidiary” and, collectively, the “Investment Management Subsidiaries”) of

                Franklin Resources Inc. (“FRI”), including the Investment Management Subsidiaries listed

                in this Item 4.  When an investment management contract (including a sub advisory

                agreement) delegates to an Investment Management Subsidiary investment discretion or

                voting power over the securities held in the investment advisory accounts that are

                subject to that agreement, FRI treats the Investment Management Subsidiary as having sole

                investment discretion or voting authority, as the case may be, unless the agreement

                specifies otherwise. Accordingly, each Investment Management Subsidiary reports on

                Schedule 13G that it has sole investment discretion and voting authority over the

                securities covered by any such investment management agreement, unless otherwise noted in

                this Item 4.  As a result, for purposes of Rule 13d‑3 under the Act, the Investment

                Management Subsidiaries listed in this Item 4 may be deemed to be the beneficial owners

                of the securities reported in this Schedule 13G.

     

                Beneficial ownership by Investment Management Subsidiaries and other FRI affiliates is

                being reported in conformity with the guidelines articulated by the SEC staff in Release

                No. 34‑39538 (January 12, 1998) (the “1998 Release”) relating to organizations, such as

                FRI, where related entities exercise voting and investment powers over the securities

                being reported independently from each other. The voting and investment powers held by

                each of FRI’s affiliates whose ownership of securities is disaggregated from that of FRI

                in accordance with the 1998 Release (“FRI Disaggregated Affiliates”) are exercised

                independently from FRI and from all other Investment Management Subsidiaries (FRI, its

     

     

     


     
     

          CUSIP NO. 04746L104                           13G                            Page 7 of 12

     

              affiliates and the Investment Management Subsidiaries other than FRI Disaggregated

              Affiliates are collectively, “FRI Aggregated Affiliates”). Furthermore, internal policies

              and procedures of, on the one hand, FRI Disaggregated Affiliates, and, on the other hand,

              FRI establish informational barriers that prevent the flow among, on the one hand, FRI

              Disaggregated Affiliates (including preventing the flow between such entities), and, on

              the other hand, the FRI Aggregated Affiliates of information that relates to the voting

              and investment powers over the securities owned by their respective investment management

              clients. Consequently, FRI Disaggregated Affiliates report the securities over which they

              hold investment and voting power separately from the FRI Aggregated Affiliates for

              purposes of Section 13 of the Act.

     

              Charles B. Johnson and Rupert H. Johnson, Jr. (the “Principal Shareholders”) each own in

              excess of 10% of the outstanding common stock of FRI and are the principal stockholders

              of FRI.  FRI and the Principal Shareholders may be deemed to be, for purposes of Rule

              13d‑3 under the Act, the beneficial owners of securities held by persons and entities for

              whom or for which FRI subsidiaries provide investment management services.  The number of

              shares that may be deemed to be beneficially owned and the percentage of the class of

              which such shares are a part are reported in Items 9 and 11 of the cover pages for FRI

              and each of the Principal Shareholders. FRI, the Principal Shareholders and each of the

              Investment Management Subsidiaries disclaim any pecuniary interest in any of such

              securities. In addition, the filing of this Schedule 13G on behalf of the Principal

              Shareholders, FRI and the FRI Aggregated Affiliates, as applicable, should not be

              construed as an admission that any of them is, and each of them disclaims that it is, the

              beneficial owner, as defined in Rule 13d‑3, of any of the securities reported in this

              Schedule 13G.

     

              FRI, the Principal Shareholders, and each of the Investment Management Subsidiaries

              believe that they are not a “group” within the meaning of Rule 13d‑5 under the Act and

              that they are not otherwise required to attribute to each other the beneficial ownership

              of the securities held by any of them or by any persons or entities for whom or for which

              the Investment Management Subsidiaries provide investment management services.

     

     

                          (a)  Amount beneficially owned:

     

                                    0

     

                          (b)  Percent of class:

     

                                    0.0%

     

                          (c)  Number of shares as to which the person has:

     

                                    (i) Sole power to vote or to direct the vote

     

                                            Franklin Resources, Inc.:                                          0

     

                                            Charles B. Johnson:                                                0

     

                                            Rupert H. Johnson, Jr.:                                            0

     

                                           

                                (ii) Shared power to vote or to direct the vote

     

                                            0

     

     

                              (iii) Sole power to dispose or to direct the disposition of

     

                                            Franklin Resources, Inc.:                                          0

     

                                            Charles B. Johnson:                                                0

     

                                            Rupert H. Johnson, Jr.:                                            0

     

                                           

     


     
     

          CUSIP NO. 04746L104                           13G                            Page 8 of 12

     

                               (iv)  Shared power to dispose or to direct the disposition of

     

                                            0

     

              Item 5.  Ownership of Five Percent or Less of a Class

     

                                If this statement is being filed to report the fact that as of the date hereof

                                the reporting person has ceased to be the beneficial owner of more than five

                                percent of the class of securities, check the following [X].

     

     

              Item 6.  Ownership of More than Five Percent on Behalf of Another Person

     

                                The clients of the Investment Management Subsidiaries, including investment

                                companies registered under the Investment Company Act of 1940 and other managed

                                accounts, have the right to receive or power to direct the receipt of dividends

                                from, and the proceeds from the sale of, the securities reported herein. 

     

     

              Item 7.  Identification and Classification of the Subsidiary Which Acquired the

                                Security Being Reported on By the Parent Holding Company

                       

                                Not Applicable

                               

              Item 8.  Identification and Classification of Members of the Group

     

                                Not Applicable

     

              Item 9.  Notice of Dissolution of Group

     

                                Not Applicable

     


     
     

          CUSIP NO. 04746L104                           13G                            Page 9 of 12

     

              Item 10.  Certification

     

              By signing below I certify that, to the best of my knowledge and belief, the securities

              referred to above were acquired and are held in the ordinary course of business and

              were not acquired and are not held for the purpose of or with the effect of changing or

              influencing the control of the issuer of the securities and were not acquired and are

              not held in connection with or as a participant in any transaction having that purpose

              or effect, other than activities solely in connection with a nomination under §

              240.14a‑11.

     

              This report shall not be construed as an admission by the persons filing the report

              that they are the beneficial owner of any securities covered by this report.

     

              Exhibits.

                                Exhibit A Joint Filing Agreement

                                Exhibit B Limited Powers of Attorney for Section 13 Reporting Obligations

                               

                                                                                      SIGNATURE

     

              After reasonable inquiry and to the best of my knowledge and belief, I certify that

              the information set forth in this statement is true, complete and correct.

     

              Dated:  January 24, 2023

     

              Franklin Resources, Inc.

     

              Charles B. Johnson

     

              Rupert H. Johnson, Jr.

     

             

     

              By:     /s/LORI A. WEBER

                             ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

                             Lori A. Weber

                             Assistant Secretary of Franklin Resources, Inc.

                             Attorney‑in‑Fact for Charles B. Johnson pursuant to Power of Attorney

                             attached to this Schedule 13G

     

                             Attorney‑in‑Fact for Rupert H. Johnson, Jr. pursuant to Power of Attorney

                             attached to this Schedule 13G

     

        


     
     

          CUSIP NO. 04746L104                           13G                            Page 10 of 12

     

              EXHIBIT A

     

              JOINT FILING AGREEMENT

     

              In accordance with Rule 13d‑1(k) under the Securities Exchange Act of 1934, as

              amended, the undersigned hereby agree to the joint filing with each other of the

              attached statement on Schedule 13G and to all amendments to such statement and that

              such statement and all amendments to such statement are made on behalf of each of

              them.

     

              IN WITNESS WHEREOF, the undersigned have executed this agreement on January 24, 2023.

     

              Franklin Resources, Inc.

     

              Charles B. Johnson

     

              Rupert H. Johnson, Jr.

     

             

     

              By:     /s/LORI A. WEBER

                             ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

                             Lori A. Weber

                             Assistant Secretary of Franklin Resources, Inc.

                             Attorney‑in‑Fact for Charles B. Johnson pursuant to Power of Attorney

                             attached to this Schedule 13G

     

                             Attorney‑in‑Fact for Rupert H. Johnson, Jr. pursuant to Power of Attorney

                             attached to this Schedule 13G

     

     

     

     

             

     

                            

     

     

     


     
     

          CUSIP NO. 04746L104                           13G                            Page 11 of 12

     

                                                                                           EXHIBIT B

                                                                                LIMITED POWER OF ATTORNEY

                                                         FOR SECTION 13 AND 16 REPORTING OBLIGATIONS

        Know all by these presents, that the undersigned hereby makes, constitutes and appoints each

      of Alison E. Baur, Steven J. Gray, Beth McAuley O’Malley, Thomas C. Merchant, Kimberly H.

      Novotny, Virginia E. Rosas, Navid J. Tofigh and Lori A. Weber each acting individually, as the

      undersigned’s true and lawful attorney‑in‑fact, with full power and authority as hereinafter

      described on behalf of and in the name, place and stead of the undersigned to:

                1. prepare, execute, acknowledge, deliver and file Forms ID, Schedules 13D and 13G, and

      Forms 3, 4 and 5 (including any amendments thereto and any related documentation) with the

      United States Securities and Exchange Commission and any national securities exchanges

      relating to Franklin Resources, Inc. (“FRI”) and/or any registered closed‑end company to which

      an affiliate of FRI is an investment adviser (each, a “Reporting Entity”), as considered

      necessary or advisable under Regulation S‑T and Sections 13(d) and 16(a) of the Securities

      Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from

      time to time (the “Exchange Act”); and

                2. seek or obtain, as the undersigned’s representative and on the undersigned’s behalf,

      information on transactions in the securities of any Reporting Entity from any person,

      including brokers, employee benefit plan administrators and trustees, and the undersigned

      hereby authorizes any such person to release any such information to the undersigned and

      approves and ratifies any such release of information; and

                3. perform any and all other acts which in the discretion of such attorney‑in‑fact are

      necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

                The undersigned acknowledges that:

                1. this Limited Power of Attorney authorizes, but does not require, each such

      attorney‑in‑fact to act in their discretion on information provided to such attorney‑in‑fact

      without independent verification of such information;

                2. any documents prepared and/or executed by any such attorney‑in‑fact on behalf of the

      undersigned pursuant to this Limited Power of Attorney will be in such form and will contain

      such information and disclosure as such attorney‑in‑fact, in his or her discretion, deems

      necessary or desirable;

                3. none of FRI, any Reporting Entity nor any of such attorneys‑in‑fact assumes (i) any

      liability for the undersigned’s responsibility to comply with the requirements of the Exchange

      Act, (ii) any liability of the undersigned for any failure to comply with such requirements,

      or (iii) any obligation or liability of the undersigned for profit disgorgement under Section

      16(b) of the Exchange Act; and

                4. this Limited Power of Attorney does not relieve the undersigned from responsibility

      for compliance with the undersigned’s obligations under the Exchange Act, including without

      limitation, the reporting requirements under Section 16 of the Exchange Act.

                The undersigned hereby gives and grants each of the foregoing attorneys‑in‑fact full

      power and authority to do and perform all and every act and thing whatsoever requisite,

      necessary or appropriate to be done in and about the foregoing matters as fully to all intents

      and purposes as the undersigned might or could do if present, hereby ratifying all that each

      such attorney‑in‑fact of, for and on behalf of the undersigned, shall lawfully do or cause to

      be done by virtue of this Limited Power of Attorney, and indemnifies each of the foregoing

      attorneys‑in‑fact against any loss of any nature whatsoever arising in connection therewith.

                This Limited Power of Attorney shall remain in full force and effect until revoked by the

      undersigned in a signed writing delivered to each such attorney‑in‑fact.

                IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be

      executed as of this 16th day of August, 2021.

                                                                 /s/CHARLES B. JOHNSON

                                                                 Signature

                                                                 Charles B. Johnson

                                                                 Print Name

     

     


     
     

          CUSIP NO. 04746L104                           13G                            Page 12 of 12

     

                                                                           LIMITED POWER OF ATTORNEY

                                                         FOR SECTION 13 AND 16 REPORTING OBLIGATIONS

        Know all by these presents, that the undersigned hereby makes, constitutes and appoints each

      of Alison E. Baur, Steven J. Gray, Beth McAuley O’Malley, Thomas C. Merchant, Kimberly H.

      Novotny, Virginia E. Rosas, Navid J. Tofigh and Lori A. Weber each acting individually, as the

      undersigned’s true and lawful attorney‑in‑fact, with full power and authority as hereinafter

      described on behalf of and in the name, place and stead of the undersigned to:

                1. prepare, execute, acknowledge, deliver and file Forms ID, Schedules 13D and 13G, and

      Forms 3, 4 and 5 (including any amendments thereto and any related documentation) with the

      United States Securities and Exchange Commission and any national securities exchanges

      relating to Franklin Resources, Inc. (“FRI”) and/or any registered closed‑end company to which

      an affiliate of FRI is an investment adviser (each, a “Reporting Entity”), as considered

      necessary or advisable under Regulation S‑T and Sections 13(d) and 16(a) of the Securities

      Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from

      time to time (the “Exchange Act”); and

                2. seek or obtain, as the undersigned’s representative and on the undersigned’s behalf,

      information on transactions in the securities of any Reporting Entity from any person,

      including brokers, employee benefit plan administrators and trustees, and the undersigned

      hereby authorizes any such person to release any such information to the undersigned and

      approves and ratifies any such release of information; and

                3. perform any and all other acts which in the discretion of such attorney‑in‑fact are

      necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

                The undersigned acknowledges that:

                1. this Limited Power of Attorney authorizes, but does not require, each such

      attorney‑in‑fact to act in their discretion on information provided to such attorney‑in‑fact

      without independent verification of such information;

                2. any documents prepared and/or executed by any such attorney‑in‑fact on behalf of the

      undersigned pursuant to this Limited Power of Attorney will be in such form and will contain

      such information and disclosure as such attorney‑in‑fact, in his or her discretion, deems

      necessary or desirable;

                3. none of FRI, any Reporting Entity nor any of such attorneys‑in‑fact assumes (i) any

      liability for the undersigned’s responsibility to comply with the requirements of the Exchange

      Act, (ii) any liability of the undersigned for any failure to comply with such requirements,

      or (iii) any obligation or liability of the undersigned for profit disgorgement under Section

      16(b) of the Exchange Act; and

                4. this Limited Power of Attorney does not relieve the undersigned from responsibility

      for compliance with the undersigned’s obligations under the Exchange Act, including without

      limitation, the reporting requirements under Section 16 of the Exchange Act.

                The undersigned hereby gives and grants each of the foregoing attorneys‑in‑fact full

      power and authority to do and perform all and every act and thing whatsoever requisite,

      necessary or appropriate to be done in and about the foregoing matters as fully to all intents

      and purposes as the undersigned might or could do if present, hereby ratifying all that each

      such attorney‑in‑fact of, for and on behalf of the undersigned, shall lawfully do or cause to

      be done by virtue of this Limited Power of Attorney, and indemnifies each of the foregoing

      attorneys‑in‑fact against any loss of any nature whatsoever arising in connection therewith.

                This Limited Power of Attorney shall remain in full force and effect until revoked by the

      undersigned in a signed writing delivered to each such attorney‑in‑fact.

                IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be

      executed as of this 16th day of August, 2021.

                                                                 /s/RUPERT H. JOHNSON, JR.

                                                                 Signature

                                                                 Rupert H. Johnson, Jr.

                                                                 Print Name

     

     

     

     

     

     

     

    Get the next $ATHA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ATHA

    DatePrice TargetRatingAnalyst
    9/19/2024$5.00 → $0.50Outperform → Neutral
    Mizuho
    9/4/2024Buy → Neutral
    Rodman & Renshaw
    9/4/2024Buy → Neutral
    BTIG Research
    9/4/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/19/2024$22.00Buy
    Rodman & Renshaw
    10/17/2022$20.00Mkt Perform → Mkt Outperform
    JMP Securities
    7/7/2022$6.00Buy
    Mizuho
    6/23/2022$36.00 → $5.00Buy → Hold
    Stifel
    More analyst ratings

    $ATHA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

      Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development On-track to enable initiation of a clinical trial in ALS patients in late 2025 BOTHELL, Wash., May 13, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the Company will present data from a Phase 1 clinical trial of ATH-1105 in healthy volunteers at the 4th Annual ALS drug Development Summit taking place from May 1

      5/13/25 11:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

      Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing ALS patients in late 2025 BOTHELL, Wash., May 09, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended March 31, 2025, and provided recent pipeline and business updates. "We continue to focus our efforts on advancing ATH-1105 as a potential therapy for ALS. ATH-1105 has shown encouraging ev

      5/9/25 4:05:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

      Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS) On-track to enable dosing ALS patients in 2025 BOTHELL, Wash., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2024, and provided recent pipeline and business updates. "We look forward to the opportunity to continue to advance ATH-1105 as a potential therapy for ALS, which in various preclinical models has demonstrated a consistent ability to

      2/27/25 4:05:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Athira Pharma downgraded by Mizuho with a new price target

      Mizuho downgraded Athira Pharma from Outperform to Neutral and set a new price target of $0.50 from $5.00 previously

      9/19/24 7:34:53 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma downgraded by Rodman & Renshaw

      Rodman & Renshaw downgraded Athira Pharma from Buy to Neutral

      9/4/24 8:27:09 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma downgraded by BTIG Research

      BTIG Research downgraded Athira Pharma from Buy to Neutral

      9/4/24 7:28:38 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF SCIENTIFIC OFFICER Church Kevin was granted 10,000 shares, converted options into 36,666 shares and sold $2,502 worth of shares (8,526 units at $0.29), increasing direct ownership by 29% to 168,901 units (SEC Form 4)

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      7/2/25 4:35:30 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Litton Mark James converted options into 108,334 shares and sold $7,374 worth of shares (25,123 units at $0.29), increasing direct ownership by 34% to 325,802 units (SEC Form 4)

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      7/2/25 4:34:41 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF MEDICAL OFFICER San Martin Javier converted options into 46,666 shares and sold $3,182 worth of shares (10,842 units at $0.29), increasing direct ownership by 100% to 71,665 units (SEC Form 4)

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      7/2/25 4:33:46 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Romano Kelly A bought $100,051 worth of shares (42,400 units at $2.36), increasing direct ownership by 111% to 80,715 units (SEC Form 4)

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      6/25/24 7:21:55 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Perceptive Advisors Llc bought $1,462,895 worth of shares (605,686 units at $2.42) (SEC Form 4)

      4 - Athira Pharma, Inc. (0001620463) (Issuer)

      12/29/23 5:24:55 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    SEC Filings

    See more
    • SEC Form 144 filed by Athira Pharma Inc.

      144 - Athira Pharma, Inc. (0001620463) (Subject)

      7/1/25 7:37:16 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Athira Pharma Inc.

      144 - Athira Pharma, Inc. (0001620463) (Subject)

      7/1/25 7:36:09 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Athira Pharma Inc.

      144 - Athira Pharma, Inc. (0001620463) (Subject)

      7/1/25 7:33:12 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Athira Pharma Inc.

      SC 13G/A - Athira Pharma, Inc. (0001620463) (Subject)

      11/14/24 4:17:23 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Athira Pharma Inc.

      SC 13G - Athira Pharma, Inc. (0001620463) (Subject)

      11/7/24 1:15:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Athira Pharma Inc.

      SC 13D/A - Athira Pharma, Inc. (0001620463) (Subject)

      10/31/24 4:16:28 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Leadership Updates

    Live Leadership Updates

    See more
    • Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

      BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 years of drug development experience and a proven track record leading cross-functional product teams to drive global development and commercialization strategies for multiple drugs across large and rare diseases with significant unmet medical need. "We are pleased to welcome Javier to the team and are confident his insights and guidance will be i

      4/15/24 7:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

      BOTHELL, Wash., May 22, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Andrew Gengos as Chief Financial Officer and Chief Business Officer, effective immediately. Mr. Gengos replaces Glenna Mileson, who is retiring after serving as Athira's Chief Financial Officer for eight years. "On behalf of the entire Athira team, we thank Glenna for her many years of service, particularly for her stewardship during our transition to a publicly traded company, and wish her well in retirement," said Mark Litton, Ph.D

      5/22/23 7:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ric Kayne Publishes Investor Presentation Highlighting Urgent Need for Changes to Athira's Board of Directors

      New, Independent, Shareholder-Centric Directors are Needed to Ensure ATH-1017's Significant Potential is Realized and Reverse Destruction of Shareholder Value by Athira's Current Board Launches Campaign Website with Additional Information for Shareholders: www.SaveAthira.com Urges Athira Shareholders to VOTE their BLUE Proxy Card TODAY Richard A. (Ric) Kayne, who together with his affiliates beneficially owns approximately 4.8% of the outstanding shares of common stock of Athira Pharma, Inc. (NASDAQ:ATHA) ("Athira" or the "Company"), today released a detailed presentation to Athira's shareholders demonstrating the need for immediate change on the Company's Board of Directors (the "Board"

      4/25/22 8:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Breaking: Stock Acquired at Athira Pharma Inc. on Jun 25

      Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto

      6/26/24 3:07:15 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATHA
    Financials

    Live finance-specific insights

    See more
    • Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update

      On track to report topline data from ACT-AD Phase 2 Alzheimer's disease study in 2Q22 Expect to complete enrollment in LIFT-AD Phase 3 Alzheimer's disease study in 3Q22 Conference call today at 4:30 pm Eastern time BOTHELL, Wash., March 24, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company's financial results for the year ended December 31, 2021 and provided a clinical update. "We entered 2022 with strong momentum from the solid foundation established throughout 2021 and have made considerable progress across

      3/24/22 4:05:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022

      BOTHELL, Wash., March 17, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 and provide a business update on Thursday, March 24, 2022 following the close of the U.S. financial markets. Athira will host a conference call to discuss these results on Thursday, March 24, 2022 at 4:30 pm Eastern time (1:30 pm Pacific time). In order to participate in the conference call, please dial 833-614-1520 (domestic) or 516-575-8710 (internationa

      3/17/22 7:00:00 AM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer

      Special Committee of the Board of Directors has concluded its investigation of Dr. Leen Kawas's Doctoral ResearchConference call to be held October 21, 2021 at 4:30 pm ET BOTHELL, Wash., Oct. 21, 2021 (GLOBE NEWSWIRE) --  Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Mark Litton, Ph.D., M.B.A. as Chief Executive Officer of Athira. Dr. Litton succeeds Dr. Leen Kawas, who has resigned from her position as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors. Dr. Litton will also

      10/21/21 4:05:00 PM ET
      $ATHA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care